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Herpes simplex virus-1 entrapped 
in Candida albicans biofilm displays decreased 
sensitivity to antivirals and UVA1 laser treatment
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Abstract 
Background: Recently, we published data suggesting a mutualistic relationship between HSV‑1 and Candida. 
albicans; in particular: (a) HSV‑1 infected macrophages are inhibited in their anti‑Candida effector function and (b) 
Candida biofilm protects HSV‑1 from inactivation. The present in vitro study is aimed at testing the effects of Candida 
biofilm on HSV‑1 sensitivity to pharmacological and physical stress, such as antiviral drugs (acyclovir and foscarnet) 
and laser UVA1 irradiation. We also investigated whether fungus growth pattern, either sessile or planktonic, influ‑
ences HSV‑1 sensitivity to antivirals.
Methods: Mature Candida biofilms were exposed to HSV‑1 and then irradiated with laser light (UVA1, 355 λ). In 
another set of experiments, mature Candida biofilm were co‑cultured with HSV‑1 infected VERO cells in the presence 
of different concentrations of acyclovir or foscarnet. In both protocols, controls unexposed to laser or drugs were 
included. The viral yield of treated and untreated samples was evaluated by end‑point titration. To evaluate whether 
this protective effect might occur in relation with a different growth pattern, HSV‑1 infected cells were co‑cultured 
with either sessile or planktonic forms of Candida and then assessed for susceptibility to antiviral drugs.
Results: UVA1 irradiation caused a 2 Log reduction of virus yield in the control cultures whereas the reduction was 
only 1 Log with Candida biofilm, regardless to the laser dose applied to the experimental samples (50 or 100 J/cm2). 
The presence of biofilm increased the  IC90 from 18.4–25.6 J/cm
2. Acyclovir caused a 2.3 Log reduction of virus yield in 
the control cultures whereas with Candida biofilm the reduction was only 0.5 Log; foscarnet determined a reduction 
of 1.4 Log in the controls and 0.2 Log in biofilm cultures. Consequently, the  ICs50 for acyclovir and foscarnet increased 
by 4‑ and 12‑folds, respectively, compared to controls. When HSV‑1 was exposed to either sessile or planktonic fungal 
cells, the antiviral treatments caused approximately the same weak reduction of virus yield.
Conclusions: These data demonstrate that: (1) HSV‑1 encompassed in Candida biofilm is protected from inactivation 
by physical (laser) and pharmacological (acyclovir or foscarnet) treatments; (2) the drug antiviral activity is reduced at 
a similar extent for both sessile or planktonic Candida.
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Background
In most natural environments, microorganisms exist pre-
dominantly as biofilms rather than as planktonic cells [1]. 
Growing as a biofilm provides microorganisms with a 
plethora of advantages. During biofilm formation, micro-
organisms characteristically display a phenotype that is 
markedly different from that of their planktonic counter-
part, contributing to a reduced sensitivity to antimicrobial 
drugs and to host’s immune response [2–8]. In clini-
cal setting, biofilm represents an ever-growing problem 
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accounting for up to approximately 65% of infections, par-
ticularly severe in immunocompromised hosts [2].
Recently, Candida albicans biofilm has gained promi-
nence because of the increase in infections related to 
indwelling medical devices representing suitable surfaces 
for biofilm formation [9, 10]. These localized infectious 
foci can allow fungal cell detachment and dispersal, caus-
ing deep tissues candidiasis and candidemia, both associ-
ated with high mortality rates (30–50%) [11, 12]. The ability 
of C. albicans to form biofilm has a great impact on its 
pathogenicity; given the dramatically increased resistance 
to antifungal agents, such as fluconazole and amphotericin, 
biofilm-related infections are difficult to eradicate [13].
It is reasonable to envisage that in  vivo, especially 
in anatomical sites naturally harboring an abundant 
and complex resident microbiota, such biofilms likely 
occur as poly-microbial multi-layered network of differ-
ent microorganisms, experiencing both synergistic and 
antagonistic relationships. Recently, by an in vitro model, 
we demonstrated that herpes simplex virus 1 (HSV-1) 
and coxsackie virus B5 can be efficiently entrapped in and 
protected by Candida biofilm [14]; moreover, literature 
reports show that HSV-1 enhances C. albicans adher-
ence, biofilm formation and resistance to host-mediated 
antifungal defenses [15, 16]. Such synergistic interactions 
between HSV-1 and C. albicans provide the rationale for 
the present in vitro study aimed at testing the effects of 
fungal biofilm on virus biology in terms of sensitivity to 
antiviral drugs and laser irradiation. We also investigated 
whether fungus growth pattern, either sessile or plank-
tonic, influences HSV-1 sensitivity to antivirals.
Methods
Candida albicans
The C. albicans clinical isolate 50vr, used in the present 
study, was previously characterized as biofilm producer 
and highly virulent, as assessed by an in  vivo infection 
model in Galleria mellonella [17]. C. albicans was kept 
in stock at −  20  °C and maintained for experiments by 
bi-weekly passages on Sabouraud Dextrose Agar plates. 
Fresh cultures were set the day before each experiment.
HSV‑1
The HSV-1 strain used in this work was a clinical isolate, 
identified by monoclonal antibodies, laboratory adapted 
through serial passages (> 50) on VERO cells [14, 15]. The 
virus inocula employed in the experiments consisted of cell-
free virus suspensions, obtained from centrifuged lysates 
of virus-infected VERO cells. Virus batches were titrated 
on VERO cells  (108 PFU/mL) and kept frozen in aliquots at 
− 80 °C.
Cell line
The VERO cell line was used for the all experiments. 
Cells were cultured at 37  °C and 5%  CO2 in minimum 
essential medium (MEM) with 10% (growth medium) or 
5% (maintenance medium) foetal bovine serum (FBS), 
penicillin (100 U/mL), streptomycin (100 μg/mL), cipro-
floxacin (100  μg/mL) and l-glutamine (2  mM). The cell 
line was maintained by passages in fresh medium twice 
a week.
Laser source
The Laser Alba 355 (Elettronica Valseriana, Casnigo, BG, 
Italy) was used as UVA1 laser source; it works at 355 λ, 
allowing to set different programs by combining param-
eters such as laser power, time of exposition, distance 
from the laser source and shape of the radiated area.
Antiviral drugs
Two antiviral molecules were assessed against HSV-1, 
acyclovir (Recordati SpA, Milano, Italy) and foscarnet 
(Clinigen, Burton-on-Trent, UK). Both were commercial 
products commonly used for intravenous treatment.
Biofilm formation and exposure to HSV‑1
Candida cells were grown overnight at 37  °C in yeast 
peptone dextrose (YPD), then harvested and washed 
with phosphate-buffered saline (PBS). After resuspen-
sion to 1 × 106 yeast cells/mL in MEM-10% FBS, 100 µL 
were seeded in duplicate in polystyrene, flat-bottom 
96-well cell culture plates (Euroclone S.p.A., Pero-Mi, 
Italy) and incubated at 37 °C to allow biofilm formation, 
according to reported studies [14, 18, 19]. Twenty-four 
hours later, virus inoculum (50  μL,  107  PFU/mL final 
concentration) was added to biofilm-containing wells 
and to empty control samples. The samples were incu-
bated for additional 24  h and then exposed to either 
physical or pharmacological treatments. Finally, the 
wells were scraped for 1′ with a plastic tip and the load 
of infectious virus embedded in the detached/rescued 
biofilm was titrated (see below). Each experiment was 
repeated 3–4 times and each condition was tested in 
triplicate.
In a further set of experiments aimed at assessing 
whether drug antiviral efficacy may be different when 
Candida is cultivated as biofilm or as planktonic, Candida 
was also seeded in wells with a glass cover slide on the 
bottom. In our hands, glass inhibits the Candida strain 
we used (50vr) in biofilm formation: in fact, Candida 50vr 
when cultured on glass surfaces grow in a planktonic pat-
tern (personal observation) with an hyphal mass floating 
in the culture medium.
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Virus titration
In each experiment, HSV-1 residual titer was established 
by end-point titration. At the end of each experiment, 
plate well content was harvested by scraping for 1′ with 
a plastic tip. After centrifugation, the rescued material 
was diluted with maintenance medium on a tenfold basis 
and each dilution was seeded in duplicate onto 24 h-old 
VERO cell cultures. After a 3 day incubation at 37 °C, the 
virus titer of each sample was established as the high-
est dilution showing the typical viral cytopathic effect. 
The results, expressed as tissue culture infectious dose 
50  (TCID50)/mL, were calculated using the Reed and 
Muench formula [20].
In order to determine the Inhibitory Concentration 90 
 (IC90) or 50  (IC50) of the different treatments, the plaque 
reduction assay was used and it was performed according 
to published procedures [21]. After centrifugation of the 
rescued material, VERO cell monolayers were infected 
with tenfold serial dilutions of such material. After 1  h 
of incubation at 37 °C, virus inoculum was removed and 
each well was added with maintenance medium contain-
ing human γ-globulin anti-HSV-1 at 0.6% to neutralize 
non-penetrated virus. Medium was removed 2 days later, 
and the infected cell monolayers were fixed with meth-
anol and stained with crystal violet (CV) to count the 
cytolysis plaques: in this case, virus titer was expressed as 
plaque forming units (PFU/mL).
Laser treatment of C. albicans
The effects of UVA1 were evaluated on C. albicans to 
determine whether the laser energy could have an inhibi-
tory activity on biofilm. In particular, to test the effects of 
the laser beam on biofilm formation, Candida cells were 
exposed to the laser beam immediately after seeding the 
yeast cells in culture medium (pre-treatment) and then 
plates were incubated for 48 h to allow biofilm formation. 
Also, the effects of laser irradiation were evaluated on 
biofilm maintenance, by exposing mature biofilm to laser 
beam, namely 48  h after cell seeding (post-treatment). 
Nine different emission protocols, with energy ranging 
between 20 and 250 J/cm2, were applied. In any protocol 
tested, the laser beam had a square application and the 
tissue culture plate was set at 30 cm from the laser beam 
source. The metabolic activity and the total biomass of C. 
albicans treated and untreated biofilm were quantified by 
XTT assay and CV staining assay, respectively.
Crystal violet staining assay
CV staining assay was used to quantify the total bio-
mass of control and laser-exposed C. albicans biofilms 
[22]. Briefly, wells containing Candida biofilm or controls 
(medium only) were washed 3 times with 200 µL of PBS 
and then air dried for 5′. After fixation with 100  µL of 
methanol for 20′, the samples were stained with 100 µL of 
1% CV solution for 5′. Afterwards, each well was washed 
3 times with 200  µL of distilled water and added with 
33% acetic acid (100  µL/well). After 10  min, the optical 
densities (OD) were measured at 540  nm by a micro-
plate reader (Sunrise, Tecan Group Ltd, Männedorf, 
Switzerland).
XTT assay
The XTT colorimetric tetrazolium assay was used to 
evaluate the effects of laser treatments on total meta-
bolic activity of C. albicans biofilm [23, 24]. A commer-
cial kit (AppliChem GmbH, Darmstadt, Germany) was 
employed following the manufacturer’s instructions. 
Briefly, wells containing Candida biofilm or control wells 
(medium only), exposed or not to the laser treatments 
(as above described), were washed 3 times with 200  µL 
of PBS and then 100 µL of the colorimetric solution were 
added. After 2  h incubation in darkness at 37  °C, the 
absorbance of the colored reduction product was meas-
ured by a spectrophotometer (Sunrise, Tecan Group Ltd, 
Männedorf, Switzerland) at an OD of 450 nm.
Assessment of virus sensitivity to laser treatment in the 
presence or absence of Candida biofilm
On the basis of XTT and CV assays results (see below), 
two laser protocols were employed: program A (sub-
inhibiting treatment on Candida) which dispensed 50  J/
cm2 and program B (treatment associated with a mod-
est cytotoxicity on Candida) which dispenses 100 J/cm2. 
After 24 h incubation at 37  °C with virus, Candida bio-
films were exposed or not to laser beam. Afterwards, 
washing and scraping for 1′ were performed and the load 
of infectious virus in the detached biofilm was deter-
mined by end-point titration on VERO cells. The same 
treatment was carried out also in culture wells without 
C. albicans (controls). The  IC90 of UVA1 treatment on 
HSV-1 was determined with or without Candida biofilm. 
Thus, after 24 h of incubation at 37 °C and 5%  CO2, bio-
film and control cultures exposed to HSV-1 were treated 
with increasing laser fluencies from 10 to 60 J/cm2. After-
wards, the amount of residual HSV-1 in supernatants 
of detached materials was assessed by plaque reduction 
assay as detailed above.
Assessment of virus sensitivity to antiviral drugs in the 
presence or absence of Candida biofilm
Twenty-four hours old biofilms were exposed to VERO 
cells (2 × 105 cells/well) infected 24 h earlier with HSV-1 
(multiplicity of infection: 30 PFU/cell); the co-cultures 
were performed in growth medium in the absence or 
presence of 50  µM acyclovir or 600  µM foscarnet. In 
parallel wells (with no Candida biofilm), HSV-1 infected 
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VERO cells were treated with the same doses of the two 
antivirals. After 24 h of incubation at 37  °C, plates were 
frozen and thawed, then the viral titer of each well was 
determined by end-point titration on VERO cells.
In another set of experiments aimed at determining 
drug  IC50, twofold dilutions of each drug were added to 
wells with infected VERO cells in the presence and in the 
absence of Candida biofilm. The viral yield in each group 
was titrated 24 h later by plaque assay. For acyclovir, con-
centrations ranging from 3 to 50 µM were assayed, while 
for foscarnet from 0.019 to 2.4  mM. A dose–response 
curve was then elaborated and the  IC50 was determined 
for each drug, with or without Candida biofilm.
Statistical analysis
The data reported in figures are the mean values 
(±  standard deviation) from at least three different 
experiments performed. The results were analyzed by the 
two-tailed Student’s t test and were considered signifi-
cant when p < 0.05.
Results
Laser radiation impact on Candida biofilm
Initially, the effects of laser treatment on biofilm forma-
tion or maintenance of mature biofilm were investigated. 
Accordingly, Candida cells were treated with different 
doses of UVA1 either just after seeding onto cell culture 
plates, namely before biofilm formation (pre-treatment), 
or after 48  h of growth as biofilm (post-treatment). In 
both cases, the residual metabolic activity and the total 
biomass were assessed by XTT and CV assay, respec-
tively. The results obtained are shown in Fig.  1 (panel 
a =  pre-treatment, panel b =  post-treatment). The OD 
values of biofilm exposed to laser were similar to those of 
unexposed cultures for treatments up to a fluency of 60 J/
cm2 regardless of the fact that a pre- or a post-treatment 
had been performed. In contrast, starting from 150 J/cm2 
fluency, laser exposure caused a reduction in OD values, 
with major decrease being observed when using pretreat-
ment (upper panel) irrespective of the assay performed; 
differently, only metabolic activity (as assessed by XTT) 
but not total biomass (as assessed by CV assay) were 
impaired by laser treatment according to the Protocol B. 
Finally, 100 J/cm2 fluency caused an OD value reduction 
with a border line significance (p =  0.06) both in pre-
treatment and post-treatment (in this case only for XTT 
values). These results indicate that a low intensity laser 
radiation (≤ 60 J/cm2) significantly affects neither biofilm 
formation nor its maintenance.
Candida biofilm impact on laser antiviral activity
On the basis of the results obtained by laser radiation on 
Candida, two laser conditions were employed to carry 
out the experiments on antiviral activity of laser treat-
ment: protocol A which dispenses 50  J/cm2 (sub-inhib-
iting against biofilm) and protocol B which dispenses 
100 J/cm2 (the lowest fluency exerting a mild anti-biofilm 
activity).
In order to evaluate whether virus interaction with 
Candida biofilm can influence antiviral activity of laser 
beam, Candida biofilms co-cultured with HSV-1 infected 
cells for 24  h were exposed or not to laser beam and 
then the residual load of infectious virus in the biofilm 
was determined. The results are depicted as viral load 
reduction in Fig.  2. In control cultures without biofilm, 
protocol A reduced the amount of HSV-1 by 2 Logs (3.1 
 TCID50 vs 1.1  TCID50 for untreated and treated cul-
tures, respectively), while in biofilm cultures the decrease 
was of 1 Log (3.1  TCID50 vs 2.1  TCID50 for untreated 
and treated cultures, respectively). Similar results were 
obtained applying protocol B: in this case, in the absence 
of biofilm, virus titer decreased from 3.1  TCID50 to 1 
 TCID50, whereas in biofilm cultures the virus titers were 
3.1  TCID50 vs 1.9  TCID50 for untreated and treated cul-
tures, respectively.
The anti-HSV-1  IC90 values of laser treatment in the 
two conditions were ascertained by treating suspensions 
of HSV-1 in the presence or absence of Candida biofilm 
with increasing laser fluencies between 10 and 60 J/cm2 
and then titrated by plaques assay. The results showed an 
increased value in the presence of biofilm (18.4 J/cm2 vs 
25.6 J/cm2).
Candida biofilm impact on antiviral drug activity
Next, the influence of Candida biofilm on the antiviral 
activity of acyclovir and foscarnet was assessed. To this 
purpose, HSV-1 infected VERO cells were incubated with 
or without Candida biofilm in the presence or absence of 
antiviral drug for 24 h. The residual viral load was evalu-
ated and the results, shown as viral load reduction, are 
shown in Fig. 3. The virus titers of VERO control cultures 
(no biofilm) decreased by 2.3 Log (from 3.7  TCID50 to 
1.4  TCID50) when exposed to acyclovir and only by 0.5 
Log (from 1.6  TCID50 to 1.1  TCID50) if the treatment had 
been performed in the presence of Candida biofilm. Sim-
ilarly, using foscarnet, the virus titers decreased by 1.4 
Log in control cultures without biofilm (from 4.5  TCID50 
to 3.1  TCID50) and only by 0.2 Log when the treatment 
had been performed in the presence of Candida biofilm 
(from 3.1  TCID50 to 2.9  TCID50).
In order to establish the  IC50 values of the 2 drugs, 
HSV-1 infected VERO cells were treated with increas-
ing doses of the two antivirals in the presence or absence 
of Candida biofilm. Then residual HSV-1 infectivity was 
assessed with plaque assay. We found that acyclovir  IC50 
value increased fourfold, being 5.41 and 22.62 µM, in the 
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absence and in the presence of Candida biofilm, respec-
tively. Similar results were obtained for foscarnet: the 
 IC50 value raised from 54  µM in the absence of biofilm 
to 661 µM in VERO cultures co-incubated with Candida 
biofilm. In this case, the increase was 12-folds.
The reduction in drug antiviral activity observed does not 
depend on Candida pattern growth
Lastly, we evaluated whether the observed reduction in 
acyclovir and foscarnet efficacy against HSV-1can be 
ascribed to fungus growth manner. Thus, HSV-1 infected 
VERO cells were exposed to C. albicans grown in two dif-
ferent patterns: as a biofilm or planktonic, namely, in the 
absence or presence of a glass slide in the culture well. By 
direct microscope observation, we observed that when 
the Candida strain we used (50vr) [17] was cultured on a 
cover glass, only planktonic but not sessile Candida was 
observed.
Co-cultures of Candida and HSV-1 infected cells were 
exposed to acyclovir and foscarnet for 24 h and the viral 
loads of the different cultures were then titrated. Figure 4 
shows these results, depicted as viral load reduction. In 
control cultures without Candida, the antiviral treat-
ments caused a reduction of 4 Logs (from 5.8  TCID50 
to 0.8  TCID50) and 3.3 Logs (from 5.8  TCID50 to 2.5 
 TCID50) for acyclovir and foscarnet, respectively. In con-
trast, in cultures with Candida, the virus titers decreased 
by about 1 Log with either drug, regardless of the fact 
that the cover glass slide was or was not present: for acy-
clovir, the virus yield values were 3.3  TCID50 with plank-
tonic Candida and 3.5  TCID50 with Candida biofilm; for 





































Fig. 1 Effect of laser treatments on C. albicans. Effects of UVA1 light on formation (a) and maintenance (b) of C. albicans biofilm. Candida cells were 
exposed to the laser beam immediately after seeding in multiwell plates. The cultures were incubated for 48 h at 37 °C and then XTT assay and CV 
staining assay were carried out (a). In other sets of experiments, 48 h old Candida biofilms were exposed to the laser beam and then XTT assay and 
CV staining assay were performed (b). *p = 0.06; **p < 0.05
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Discussion
Biofilm, a major problem in clinical practice, is a struc-
tured community usually formed by different microbial 
types, mainly bacteria and fungi. Few studies are available 
on the existence of virus entrapping microbial biofilm 
and they focus mostly on aquatic biofilms [25]. Recently, 
we demonstrated in vitro that viruses, such as HSV-1 and 
Coxsackie Virus B5, while embedded in C. albicans bio-
film, still retain their infectivity [14]. We also observed 
that such intra-biofilm localization partially reduces virus 
particles sensitivity to hypochlorite. By that same in vitro 
model, here we demonstrated that Candida biofilm pro-
tected HSV-1 also from pharmacological treatments 
(acyclovir and foscarnet, the most used drugs against 
HSV-1 infections). Moreover, we documented a virucide 
activity exerted by UVA1 laser and that such activity was 
decreased in presence of Candida biofilm.
Different hypotheses can be considered to explain such 
phenomena.
Firstly, a reduced antiviral drug availability might occur 
within biofilm, due to either drug molecules engage-
ment by the EPS organic material or aspecific binding 
to fungal cells surface. Indeed, it is well known that the 
presence of many organic (proteins) or inorganic (elec-
trolytes, divalent cations) substances leads to decrease or 
complete inhibition of disinfectant activity, both in vitro 
and in vivo [26, 27]: for instance, bovine serum albumin 
is indeed used to this purpose in studies on antimicrobial 
































Fig. 2 Effect of biofilm presence on virus sensitivity to laser treat‑
ment. Effects of UVA1 at fluencies of 50 and 100 J/cm2 on infectivity 
of HSV‑1 free virus particles in the presence and in the absence of 
C. albicans biofilm. Twenty‑four hours old Candida biofilms were 
exposed to HSV‑1. After 24 h incubation, each sample was exposed 
to the laser treatment and then the culture wells were thoroughly 
washed, scraped and the amount of the residual virus end‑point 






























Fig. 3 Effect of biofilm presence on virus sensitivity to antiviral drugs. 
Antiviral effect of 50 µM acyclovir and 600 µM foscarnet on HSV‑1 
infected cells embedded or not in C. albicans biofilm. Twenty‑four 
hours old Candida biofilms were co‑cultured with HSV‑1‑infected 
VERO cells in medium containing acyclovir or foscarnet. After 24 h 
incubation, samples were frozen and thawed to lyse infected VERO, 
then the released virus was end‑point titrated. Controls (no biofilm) 































Fig. 4 Effect of sessile and planktonic Candida on antiviral drug activ‑
ity. Antiviral effect of acyclovir and foscarnet on HSV‑1 infected cells 
embedded or not (control) in C. albicans biofilm and also on infected 
cells incubated in the presence of planktonic C. albicans grown on a 
glass slide. Twenty‑four hours old Candida cells grown either with or 
without a glass slide on the well bottom were co‑cultured with HSV‑1 
infected VERO cells in acyclovir or foscarnet containing medium. After 
24 h incubation, samples were frozen and thawed to lyse infected 
cells, then the released virus was end‑point titrated. Controls (no 
biofilm) were run in parallel. *p > 0.05
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by fungal cells in the EPS might directly interact with 
drug molecules, thus impairing their efficacy. Acyclovir/
foscarnet activity was  also tested in the presence of the 
same Candida strain grown as either planktonic form 
or biofilm. In both cases, a similar reduction in antivi-
ral activity, with no significant difference, was observed, 
suggesting that EPS matrix production is not essential to 
affect drug activity. On these bases, drug-aspecific bind-
ing to fungal cells, followed or not by cell entry, could be 
the most likely hypothesis: the huge amount of biomass 
presents in both conditions, in one case forming a float-
ing mycelium network and in the other a sessile biofilm 
structure, might represent a major hindrance to virus-
drug interaction. An indirect support to this hypothesis 
comes from immunofluorescence studies: we observed 
that HSV-1 antigens or infected cells are more concen-
trated in areas with higher hyphae density (unpublished 
data). On the other hand, secretion of enzymes interact-
ing with drug molecules cannot be ruled out: in both 
growth patterns, Candida excretes a plethora of mole-
cules which could interfere with drug action.
As far as UVA1 irradiation, laser emission is currently 
used in medicine for topic treatment of different skin 
and dental diseases as well as for disinfection of surfaces, 
surgical instruments and water. We observed that when 
HSV-1 suspensions are exposed to UVA1 light at 355 λ, 
they undergo a significant inactivation. However, this 
antiviral activity is significantly affected by the presence 
of Candida biofilm. In particular, while HSV-1 infectiv-
ity was reduced by 2 Logs in the absence of biofilm, both 
at 50 or 100 J/cm2, infectivity was reduced by only 1 Log 
when biofilm was present. Consequently,  IC90 values are 
25.6 and 18.4  J/cm2 with and without biofilm, respec-
tively. This reduction in drug efficacy could be likely due 
to energy absorption by the organic mass: although most 
of the biological molecules have an absorbance peak at 
low frequencies (210–270  λ), a lower absorbance is still 
present at higher frequencies (such as 355 λ) and might 
be sufficient to subtract energy for virus inactivation.
Evidence exists on the mechanisms of laser action on 
mammalian cells; in particular, UVA1 radiation induces 
apoptosis by two mechanisms, the one triggered by sin-
glet oxygen species production, the other involving 
damages to cellular mitochondria [28]. Reactive oxygen 
species cause damages to fungal cell wall, lipid mem-
branes, nucleic acids, and react with organic molecules in 
biofilm EPS leading to a partial/complete inactivation of 
such molecules: bovine albumin represents an example. 
As said before, it can neutralize the antimicrobial activ-
ity of chemical and physical treatments. It is a globular 
structured protein of high molecular mass, with a single 
sulfhydryl (SH) group at amino acid residues (Cys-34), 
which might react with free radicals [29]. Consequently, 
the large mass of fungal cells with its huge amount of 
organic target for radiated UVA light as well as the abun-
dant organic material in the EPS might quench laser 
energy and subtract power, in turn reducing its efficacy 
on virus particles. Also heat generation by laser irradia-
tion must be considered. As a matter of fact, a photother-
molysis effect is among the mechanisms by which UVA 
irradiation exerts its biological activities [30]: this heating 
can be responsible, at least partially, for HSV-1 inactiva-
tion, considering virus fragility due to the envelope pres-
ence. The thick biofilm lime could reduce this heating 
effect. Finally, the UVA1 laser antimicrobial activity can 
be ascribed to the production of toxic molecules caused 
by its interaction with polystyrene of the tissue culture 
plate. It is well known that exposure to UVA radiation 
can cause significant degradation of many materials, 
inducing photooxidative degradation which results in 
breaking of the polymer chains and free radical produc-
tion [31]. Again, dispersion in and sequestration by the 
biofilm mass could reduce the availability for virus of 
these antimicrobial molecules.
On the whole, our present and previous data [14] show 
that HSV-1 encompassed in Candida biofilm can retain 
its infectivity and, more important, is protected from 
inactivation by chemical (hypochlorite) [14], physical 
(laser) and pharmacological treatments. Based on these 
findings, we may envisage that, in vivo, C. albicans bio-
film may represent not only a persistent reservoir of fun-
gal cells but also of infectious virus; in fact, circulating 
virus particles/virus-infected cells, during viremic infec-
tions, might be retained and protected within biofilm 
and, later on, might be released for further dissemina-
tion. Accordingly, the presence of Candida biofilm should 
represent an additional health risk factor, given its ability 
to entrap/release also viral particles, efficiently protected 
against conventional antiviral treatments; such a possibil-
ity might be dramatic especially in immunocompromised 
patients. Finally, also the chemo-physical procedures 
aimed at warranting virus decontamination of materials 
and surfaces should be carefully reconsidered, since their 
efficacy might be drastically impaired by the concomitant 
presence of fungal biofilm.
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